Shares of Longeveron Inc (NASDAQ:LGVN) are trading higher on Wednesday with a session volume of 78.36 million compared to the average volume of 8.34 million, as per data from Benzinga Pro.
The company announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B for mild Alzheimer’s Disease.
Lomecel-B is a proprietary, scalable, allogeneic cellular investigational therapy being evaluated across multiple indications, including Alzheimer’s Disease (Phase 2a completed), Aging-related Frailty (Phase 2b completed), and hypoplastic left heart syndrome (HLHS) (Phase 2b on-going).
It means the treatment, made from cells that can be ...